Related Experiment Video
Updated: Jun 14, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Bench to bedside targeting of FLT3 in acute leukemia
1Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.
Abstract:
FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules are in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.
Insights
Targeting FMS-Like-Tyrosine kinase-3 (FLT3) mutations in acute myeloid leukemia (AML) shows promise. While current FLT3 inhibitors offer limited responses, ongoing research and combination therapies aim to improve patient survival.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FMS-Like-Tyrosine kinase-3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML), associated with poor prognosis.
- Targeting FLT3 is a key strategy in AML treatment, with several inhibitors in development.
Purpose of the Study:
- To review the current landscape of FLT3 inhibitors in AML treatment.
- To assess the efficacy and limitations of existing and emerging FLT3-targeted therapies.
Main Methods:
- Review of preclinical and clinical studies on FLT3 inhibitors in AML.
- Analysis of monotherapy and combination therapy trial data.
Main Results:
- FLT3 inhibition is necessary for clinical response, but current agents show limited efficacy.
- Combination of FLT3 inhibitors with chemotherapy improves remission rates but not survival.
- Sorafenib, an approved FLT3 inhibitor, has activity but rarely achieves complete response.
Conclusions:
- Development of effective FLT3 inhibitors for AML is ongoing.
- Sustained and effective FLT3 inhibition is crucial for successful treatment.
- Future research focuses on optimizing FLT3-targeted therapies, including combination strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...